Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes - Wikidata - wikimedia - TriplyDB

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

http://www.wikidata.org/entity/Q34699217

about

Diabetes mellitus in elderly Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.Antidiabetic Effects of Simple Phenolic Acids: A Comprehensive Review.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: Rationale and evidences.Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation.

P2860

Q26773548-CFEB9C5E-1319-46EB-AEE9-CCA4C8E3069B Q33625207-F7694B6D-8BC8-4C90-B61F-B5FA89DBAAFA Q37588842-C38083CF-3E85-4BE9-8AA5-4D4B252EC49C Q38569449-5C0D277D-003A-46CA-A01E-FDB681681243 Q38658576-A7762DF1-C2EA-4DE4-B6FE-F1346A4F7ED7 Q38663903-16F61B64-73C6-46F6-B29B-4598EA92D574 Q38664568-531C1872-236A-4C1D-B3CA-F0C79089196C Q41227936-00DBE702-FE51-4C17-9A8E-EE7780110F09

P2860

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

http://www.wikidata.org/entity/Q34699217

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@ast

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@en

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@nl

type

label

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@ast

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@en

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@nl

prefLabel

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@ast

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@en

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@nl

P1433

Q34699217-88F4DFA3-A7AE-44B2-AAF2-6B170BCC6733

P1476

Q34699217-7D8A260D-4C2F-4588-8154-E1C597992F35

P2093

Q34699217-47FCC8D2-C9FF-4EE7-AC34-A10BA811433E

P2860

Q34699217-0DE6C31A-DF67-4EF8-854D-CFD9D7E60E32

Q34699217-11F2E4A2-AA91-4902-8286-B4047B76B3EC

Q34699217-3055927E-C3DD-4B5F-BC96-F19152BE0D6F

Q34699217-3635919C-7194-42EA-B5D6-4B3DA844BDEA

Q34699217-3B45E313-EC41-4CF9-87B3-D4ABC8E8E0A3

Q34699217-46572108-BE65-4D5F-B9BC-E62A3681F95B

Q34699217-4C9F664A-7F99-4ADD-B39D-8AFA3E828472

Q34699217-643E67CC-FC09-4F1C-B68B-EA955227EEDF

Q34699217-669696B3-C05B-4F03-AB10-8B6282F61A60

Q34699217-676B3C60-E3FB-44A2-BD20-8DCF5CE9EDA1

P304

Q34699217-679094BE-3B75-4C0C-A8DE-2835FD6BCF3D

P31

Q34699217-E1F7A17D-6ADC-430B-B94B-E8AD22B7FDB7

P356

Q34699217-BA7B18C9-3063-4EAC-B2BD-854B1F2160EE

P433

Q34699217-6AC26939-AA49-4C5F-8FF3-A332FCB7FEE7

P478

Q34699217-B4861D2A-5C60-4D19-A3FB-2508BA563295

P577

Q34699217-4E125D41-A128-4FCF-8865-30B4B673572E

P5875

Q34699217-A53F7FD3-3927-4F2C-829A-920D82124B97

P698

Q34699217-BD4C5A5A-9C38-40B9-A447-B5A3486CAFF0

P921

Q34699217-86FABF93-5A7D-423F-85CD-B540648B5D1F

Q34699217-F4889373-E958-4518-9982-0DD813E9AC85

P932

Q34699217-B958BE70-D572-4AE5-85D2-3EAEF46586EC

P356

P1433

World journal of diabetes

P1476

Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes

@en

P2093

Nasser Mikhail

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example.

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

P304

854-859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4239/WJD.V5.I6.854

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269712721

http://www.w3.org/2001/XMLSchema#string

P698

25512787

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4265871

http://www.w3.org/2001/XMLSchema#string